Dotmatics acquires BioBright to accelerate laboratory data automation
Dotmatics has agreed to acquire BioBright, an expert in automating the flow of data from laboratory instruments to a secure cloud.
BioBright’s solutions enable scientists to automate the collection of data from in-house and externally networked sources, and then standardise and analyse crucial experimental data with validation and integrity checks built in. It began operations in 2015 and was funded early on by the Defense Advanced Research Projects Agency to create a secure data collection platform for complex biological data. The team comprises experience from leading organizations in the space, including MIT, Harvard, Cornell, IBM, PerkinElmer and Ginkgo Bioworks.
The acquisition will create a combination of lab data capture, data processing, electronic lab notebook (ELN) and data analytics capability from a single supplier. All data coming from instruments, users or CROs will flow into a centralised informatics platform and through end-to-end workflows, allow scientists to increase lab efficiency and make better informed decisions. Successful transition to full digitalisation in the form of a fully integrated ‘lab of the future’ is recognised throughout the life science industry and other scientific industries, as being critical to turning around the productivity deficit in research. It will also provide the solid and secure data foundation which will be key to improving innovation through better informed decision-making for scientists aided by next generation AI and machine learning.
The combined portfolio will be available from Dotmatics.
Dr Stephen Gallagher, Co-Founder and Chief Executive Officer Dotmatics, commented: “This is an exciting milestone in the history of Dotmatics and also hugely significant for our customers and the wider industry. For the first time world-leading informatics and lab data automation platforms are being brought together under a single vendor. Through complementary technologies, shared scientific expertise and industry insight, we will dramatically accelerate Dotmatics’ ability to innovate and drive lab data automation.”
Charles Fracchia, Co-Founder and Chief Executive Officer BioBright, added: “Scientific research has moved from being process-driven to data-centric. Scientists are inferring the results of experiments by analysing more data than ever, and real-time data processing of terabytes of data is enabling analyses which were simply not possible in the manual era. Companies that own the cleanest, best-annotated data will be the most successful in making ground-breaking discoveries within this new paradigm. We are excited to combine BioBright with Dotmatics to build out a unique end-to-end offering that will allow our customers to achieve their data-driven future.”
The Apocalyptic Horsemen of Drug Discovery and Development READ MORE
A roadmap for achieving self-sustainability of academic high throughput screening core facilities READ MORE
Editing the Human Genome: Role in Functional Genomics and Translational Medicine READ MORE
New Tools Increase Accessibility to High Content Screening Assays READ MORE
The Application of iPS Cells and Differentiated Neuronal Cells To Advance Drug Discovery READ MORE
In Vivo Imaging In Drug Development: Gamma Scintigraphy READ MORE
Innovate While Derisking Drug Development: Yes We Can! READ MORE
Stem Cells: Cell-Based Assays and the World of Small Molecules READ MORE
Pharmaceutical & biomedical research likely to use $1 billion worth of microfluidics devices by 2016 READ MORE
Asian Innovation: A Unique Opportunity For The Pharmaceutical Industry READ MORE